Triple Action
Triple Action
HYDRATES |
SOFTENS |
GENTLY RELIEVES1-3 |
|
HYDRATES |
SOFTENS |
GENTLY RELIEVES1-3 |
Start patients on MiraLAX® first
Start patients on MiraLAX® first
MiraLAX® has a triple mechanism of action1-3 and efficacy proven in multiple clinical trials.4-8
In a recent survey of 300 GIs,
90% said that MiraLAX® is the OTC laxative they trust most9,a,b
90% said that MiraLAX® is the OTC laxative they trust most9,a,b
aBased on a survey that asked 300 gastroenterologists to rate the important factors in choosing an OTC medication for adults with occasional constipation and how well MiraLAX® met those needs. HCPs selected from a set of options based on their clinical experience. Survey details and data are available upon request.9
bGIs rated the strength of their agreement with this statement ≥5 on a scale of 1-7.9
Robust clinical support4-8—Grade A recommendation, Level 1 evidence8
Robust clinical support4-8—Grade A recommendation, Level 1 evidence8
Higher rating than fibers or stool softeners8
In a review spanning more than 2 decades of evidence, MiraLAX® received a stronger recommendation than stool softeners and fiber supplements.8
CLINICAL CORNER
What’s the link between diabetes and constipation?
What’s the link between diabetes and constipation?
Upwards of 75% of patients with diabetes mellitus report gastrointestinal symptoms12,13; up to 60% have constipation.12,14 Is there a connection? While the exact mechanism might not be known, diabetic neuropathy may play a part.14-16
In a clinical study, patients taking MiraLAX® reported relief in half the time of that reported by those who waited9
In a clinical study, patients taking MiraLAX® reported relief in half the time of that reported by those who waited9
Based on patient-reported complete satisfactory bowel movements (CSBMs) during week 1. For patients taking MiraLAX® (n=148), the median number of days to first experience a CSBM was significantly fewer than (half) that of patients taking placebo (n=64), P=0.001.
*Compared with placebo. Works in 1-3 days.
Your patients like these could benefit from starting MiraLAX® sooner
Your patients like these could benefit from starting MiraLAX® sooner
MiraLAX® is supported by 25 years of safe and effective use
It was FDA approved in 1999 as an Rx, and as an OTC product in 2006.17,18
Patient resources
Patient resources
Access downloadable tools to help support your patients.
Click to expand.
References: 1. Schiller LR, Emmett M, Santa Ana CA, Fordtran JS. Osmotic effects of polyethylene glycol. Gastroenterology. 1988;94(4):933-941. doi:10.1016/0016-5085(88)90550-1 2. Hammer HF, Santa Ana CA, Schiller LR, Fordtran JS. Studies of osmotic diarrhea induced in normal subjects by ingestion of polyethylene glycol and lactulose. J Clin Invest. 1989;84(4):1056-1062. doi:10.1172/JCI114267 3. Andrews CN, Storr M. The pathophysiology of chronic constipation. Can J Gastroenterol. 2011;25(Suppl B):16B-21B. 4. DiPalma JA, Cleveland MvB, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol. 2007;102:1436-1441. doi:10.1111/j.1572-0241.2007.01199.x 5. Cleveland MvB, Flavin DP, Ruben RA, Epstein RM, Clark GE. New polyethylene glycol laxative for treatment of constipation in adults: a randomized, double-blind, placebo-controlled study. South Med J. 2001;94(5):478-481. 6. DiPalma JA, Cleveland MB, McGowan J, Herrera JL. A comparison of polyethylene glycol laxative and placebo for relief of constipation from constipating medications. South Med J. 2007;100(11):1085-1090. doi:10.1097/SMJ.0b013e318157ec8f 7. Lee-Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev. 2010;(7):CD007570. doi:10.1002/14651858.CD007570.pub2 8. Rao SSC, Brenner DM. Efficacy and safety of over-the-counter therapies for chronic constipation: an updated systematic review. Am J Gastroenterol. 2021;116(6):1156-1181. doi:10.14309/ajg.0000000000001222 9. Data on file, Bayer Healthcare. 10. Brenner DM, Corsetti M, Drossman D, Tack J, Wald A. Perceptions, definitions, and therapeutic interventions for occasional constipation: a Rome Working Group consensus document. Clin Gastroenterol Hepatol. 2024;22:397–412. 11. Rao SSC, Brenner DM. Evidence based treatment recommendations for OTC management of chronic constipation. J Am Assoc Nurse Pract.2022;34(9):1041-1044. doi:10.1097/JXX.0000000000000760 12. Piper MS, Saad RJ. Diabetes mellitus and the colon. Curr Treat Options Gastroenterol. 2017;15(4):460-474. doi:10.1007/s11938-017-0151-1 13. Maisey A. A practical approach to gastrointestinal complications of diabetes. Diabetes Ther. 2016;7:379-386. doi:10.1007/s13300-016-0182-y 14. Vinik AI, Erbas T. Recognizing and treating diabetic autonomic neuropathy. Cleve Clin J Med. 2001;68(11):928-930, 932, 934-944. doi:10.3949/ccjm.68.11.928 15. Ihana-Sugiyama N, Nagata N, Yamamoto-Honda R, et al. Constipation, hard stools, fecal urgency, and incomplete evacuation, but not diarrhea is associated with diabetes and its related factors. World J Gastroenterol. 2016;22(11):3252-3260. doi:10.3748/wjg.v22.i11.3252 16. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26(5):1553-1579. doi:10.2337/diacare.26.5.1553 17. US Food and Drug Administration. NDA 20-698. Approval letter for MiraLAX powder. February 18, 1999. 18. US Food and Drug Administration. NDA 22-015. Approval letter for MiraLAX powder OTC. October 6, 2006. 19. Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association medical position statement on constipation. Gastroenterology. 2013;144(1):211-217. doi:10.1053/j.gastro.2012.10.029
